Mobidiag, a Finnish biotech firm developing assays that detect sepsis, herpes, and bone and joint infections, this week announced a new, higher-throughput platform.

The company, which last October achieved a CE-IVD marking for its sepsis-detection test, is also seeking CE-IVD marks for its herpes and bone and joint assays, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.